Literature DB >> 33845919

A case of pericarditis caused by Mycoplasma hyorhinis in a weaned piglet.

Martina Ustulin1, Erica Rossi2, Denis Vio3.   

Abstract

BACKGROUND: Mycoplasma hyorhinis (M. hyorhinis) is a bacterium commonly found in the upper respiratory tract of healthy pigs and an agent of polyserositis and polyarthritis. Moreover, it can carry antibiotic resistance genes (Wu et al, Vet. Microbiol. 76: 25-30, 2000). Economic losses caused by M. hyorhinis can be reduced by antibiotic therapy, however, isolation and antimicrobic susceptibility profile are rarely performed. CASE
PRESENTATION: The present report describes a case of pericarditis caused by M. hyorhinis in a weaned piglet with respiratory symptoms and reduced growth performance. At post mortem examination, the main macroscopic finding was a severe fibrinous pericarditis and M. hyorhins was the only agent isolated from the pericardial fluid. In this strain, Minimum Inhibitory Concentration (MIC) determination revealed resistance to various antimicrobial molecules such as erythromycin, tylosin and tilmicosin.
CONCLUSION: This paper highlights the importance of including M. hyorhins in the differential diagnosis of polyserositis in swine. Moreover, due the possible presence of multidrug resistance, the determination of antimicrobial susceptibility pattern should be performed on a regular basis.

Entities:  

Keywords:  Antibiotic resistance; Mycoplasma hyorhinis; Pericarditis

Year:  2021        PMID: 33845919     DOI: 10.1186/s40813-021-00211-4

Source DB:  PubMed          Journal:  Porcine Health Manag        ISSN: 2055-5660


  9 in total

1.  Mycoplasma hyorhinis infection levels in lungs of piglets with porcine reproductive and respiratory syndrome (PRRS).

Authors:  H Kobayashi; T Morozumi; C Miyamoto; M Shimizu; S Yamada; S Ohashi; M Kubo; K Kimura; K Mitani; N Ito; K Yamamoto
Journal:  J Vet Med Sci       Date:  1996-02       Impact factor: 1.267

2.  Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones.

Authors:  P C Hannan; G D Windsor; A de Jong; N Schmeer; M Stegemann
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Antibiotic susceptibility profiles of Mycoplasma hyorhinis strains isolated from swine in Hungary.

Authors:  Katinka Bekő; Orsolya Felde; Kinga M Sulyok; Zsuzsa Kreizinger; Veronika Hrivnák; Krisztián Kiss; Imre Biksi; Ákos Jerzsele; Miklós Gyuranecz
Journal:  Vet Microbiol       Date:  2018-11-28       Impact factor: 3.293

4.  Duration of immunity for an inactivated Mycoplasma hyorhinis vaccine in pigs.

Authors:  Brian Martinson; Whitney Zoghby; Kenneth Barrett; Lawrence Bryson; Jeremy Kroll
Journal:  Vet Microbiol       Date:  2019-02-14       Impact factor: 3.293

5.  Antimicrobial susceptibility of Mycoplasma hyorhinis.

Authors:  C C Wu; T R Shryock; T L Lin; M Faderan; M F Veenhuizen
Journal:  Vet Microbiol       Date:  2000-09-15       Impact factor: 3.293

6.  Comparison of methods for in vitro testing of susceptibility of porcine Mycoplasma species to antimicrobial agents.

Authors:  E A Ter Laak; A Pijpers; J H Noordergraaf; E C Schoevers; J H Verheijden
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  The emergence of porcine circovirus 2b genotype (PCV-2b) in swine in Canada.

Authors:  Carl A Gagnon; Donald Tremblay; Peter Tijssen; Marie-Hélène Venne; Alain Houde; Seyyed Mehdy Elahi
Journal:  Can Vet J       Date:  2007-08       Impact factor: 1.008

8.  Reduction of mycoplasmal lesions and clinical signs by vaccination against Mycoplasma hyorhinis.

Authors:  Jung-Ah Lee; Min-A Hwang; Jang-Hyuck Han; Eun-Haeng Cho; Joong-Bok Lee; Seung-Yong Park; Chang-Seon Song; In-Soo Choi; Sang-Won Lee
Journal:  Vet Immunol Immunopathol       Date:  2017-12-05       Impact factor: 2.046

9.  Antimicrobial susceptibility profiles of porcine mycoplasmas isolated from samples collected in southern Europe.

Authors:  Rubén S Rosales; Ana S Ramírez; María M Tavío; Carlos Poveda; José B Poveda
Journal:  BMC Vet Res       Date:  2020-09-03       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.